GLP-1s Beyond Weight Loss: What's Proven, What's Promising, and What's Just a Headline

Educational journalism, not medical advice. Every claim here is checked against its cited sources by editor Tim Bunce — a health writer, not a physician. It isn’t specific to your situation: for health decisions, talk to your own clinician. How we work →

Why an “evidence ladder”

Almost every viral GLP-1 claim is technically “backed by a study” — but the studies are wildly different in strength. A randomised controlled trial that assigns thousands of people to drug or placebo and follows them for years is the gold standard. A real-world analysis that compares people who happened to take a drug with those who didn’t is useful but weaker, because the two groups differ in ways that are hard to fully account for. So instead of a flat list of benefits, here is the evidence ranked by how sure we actually are.

Top rung: the heart (SELECT)

The SELECT trial randomised 17,604 adults with overweight or obesity and established cardiovascular disease but without diabetes to weekly semaglutide (2.4 mg) or placebo. Over roughly 40 months, major adverse cardiovascular events — cardiovascular death, heart attack, or stroke — occurred in 6.5% on semaglutide versus 8.0% on placebo: a 20% relative risk reduction (hazard ratio 0.80) Lincoff 2023.

This is strong evidence — a large, double-blind RCT. Two honest caveats: the absolute difference was 1.5 percentage points (the “20%” is relative), and it applies to people who already have heart disease plus excess weight, not the general population. It was also funded by the manufacturer, Novo Nordisk — worth knowing, though the design is robust.

Top rung: the kidneys (FLOW)

The FLOW trial tested semaglutide in 3,533 people with type 2 diabetes and chronic kidney disease, and was stopped early for clear benefit. Compared with placebo, semaglutide cut the primary composite of major kidney events and cardiovascular death by 24% (hazard ratio 0.76), reduced major cardiovascular events by 18%, and lowered all-cause mortality by 20% Perkovic 2024.

Again: a large RCT, genuinely practice-changing for kidney medicine. And again the boundaries matter — this was people with both diabetes and kidney disease, a high-risk group, not healthy adults. Trials stopped early for benefit can also modestly overstate the effect size, so read it as “clearly helpful in this population,” not “a precise number for everyone.”

A rung down: the real-world signals

Beyond the trials, large analyses of medical records are flagging other associations. One 2026 study in the Journal of the American Heart Association emulated a trial using records from 26,408 adults with obesity and an autoimmune disease, and found GLP-1 use linked to a 44% lower risk of death, a 31% lower risk of pulmonary embolism, a 21% reduction in emergency-department visits, and a 17% lower risk of venous blood clots Sheer 2026.

Those numbers are striking — and exactly the kind that demand caution. This is observational data, not a randomised trial; the authors themselves say it cannot prove cause and effect, and better weight or blood-sugar control may explain much of it. People who take and tolerate a medication also tend to be healthier in ways records can’t capture (“healthy-user bias”). Treat a 44% mortality figure from record-keeping as a hypothesis worth testing, not a proven benefit. (In the same analysis, stroke and heart-attack reductions were small or not statistically significant — so don’t add those to the list.)

Bottom rung: the addiction frontier

GLP-1 receptors sit in the brain’s reward circuitry, and the drugs appear to dampen the dopamine-driven “wanting” that fuels cravings — which is why some people report spontaneously drinking, smoking, or snacking less. Researchers including a group led by Dr. Joji Suzuki at Brigham and Women’s Hospital are running clinical trials of GLP-1s for alcohol and opioid use disorders, and small early trials have hinted at reduced cravings Harvard Gazette 2026.

This is the most exciting and the least settled rung. As of now there is no approved use of GLP-1s for any addiction; the trials are ongoing and the existing studies are small. File it under “a genuinely interesting frontier,” not “a treatment you can ask for.”

The part the headlines skip

None of this means a GLP-1 is a good idea for everyone:

• They’re prescription drugs. The right candidate, dose, and monitoring are a clinical decision. The trial doses above are study design, not advice.
• Side effects are common and real. In SELECT, adverse events leading to permanent discontinuation hit 16.6% on semaglutide versus 8.2% on placebo — roughly double — mostly gastrointestinal (nausea, vomiting, diarrhoea) Lincoff 2023.
• The biggest trials are manufacturer-funded. That doesn’t invalidate them, but it’s worth knowing.
• The benefits above were in already-sick populations. “Off-label benefits” framing shouldn’t read as “everyone should take these.”

The bottom line

GLP-1s have earned the “more than weight loss” reputation — but the strength of the evidence drops fast as you go down the ladder. Two big randomised trials genuinely proved heart and kidney benefits in specific high-risk groups. The eye-catching extras — a 44% lower death rate in obesity-plus-autoimmune disease, or quieter addiction cravings — come from observational data or early trials, so they’re leads to watch, not facts to bank on. If a GLP-1 might be right for you, that’s a conversation with your doctor about your specific risks — not a decision to make from a headline.

This article is educational, not medical advice. GLP-1 medications are prescription-only; never start, stop, or change a medication without your prescribing clinician.

References